Oscar Health’s Unexpected Pivot: A Contrarian’s Take

According to the aforementioned SEC filing, Glynn Capital sold off 153,753 shares during the third quarter of 2025, reducing its stake in Oscar Health to a rather paltry 2,856,025 shares. These shares were valued at $54.06 million as of September 30, 2025. To the casual observer, this might seem like a rather mundane detail, but to a seasoned contrarian investor, this shift could signal something far more interesting. Oscar Health, while still holding its own as the fund’s largest holding, now represents only 17.06% of its total assets. Not exactly a ringing endorsement, but hardly a cause for panic either.







